Rockwell Medical Technologies (RMTI) 11.09 $RMTI
Rockwell Medical, Inc. Reports First Quarter 2014 Results
GlobeNewswire - Mon May 12, 3:07PM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter ended March 31, 2014.
Rockwell Medical Schedules 1st Quarter 2014 Investor Conference Call
GlobeNewswire - Tue May 06, 9:16AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2014 at 4:30pm Eastern Time.
Marginal Earnings Beat at SurModics, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:50PM CDT
SurModics (SRDX) reported lower-than-expected sales in the quarter.
Rockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data to be Presented at 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan
GlobeNewswire - Tue Apr 29, 7:08AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that an oral presentation and poster for Triferic will be presented at the 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Shares of RMTI Down 9.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 28, 9:32AM CDT
SmarTrend identified a Downtrend for Rockwell Medical Technologies (NASDAQ:RMTI) on April 7th, 2014 at $11.17. In approximately 3 weeks, Rockwell Medical Technologies has returned 9.54% as of today's recent price of $10.10.
Stock Watchout on Health Care Sector -- Research on Rockwell Medical, Stryker, Baxter Intl., and Covidien
PR Newswire - Tue Apr 22, 8:00AM CDT
The trading session on Monday, April 21, 2014 ended on a higher note as the S&P 500 finished the session 0.38% higher at 1,871.89 and the NASDAQ Composite closed at 4,121.55, up 0.64%. The Dow Jones Industrial Average finished at 16,449.25, up 0.25%. During the session, the eight out of ten sectors ended in positive. The S&P 500 Health Care Sector Index closed the day at 666.48, up 1.20%, and the same has advanced 1.75% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Rockwell Medical Inc. (NASDAQ: RMTI), Stryker Corp. (NYSE: SYK), Baxter International Inc. (NYSE: BAX) and Covidien PLC (NYSE: COV). Free technical research on RMTI, SYK, BAX and COV can be downloaded upon signing up at:
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Rockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data Selected for Three Abstract Presentations at National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 in Las Vegas, NV
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that three individual abstracts for Triferic have been selected by the National Kidney Foundation for presentation at their Spring Clinical Meetings, April 22-26, 2014 in Las Vegas, Nevada. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Today’s Top Biotech Stories: Albany Molecular Research, Rockwell Medical, and Celgene
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 24, 8:16AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Albany Molecular...
Rockwell Medical Submits New Drug Application for Triferic(TM) for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Triferic (soluble ferric pyrophosphate citrate), the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. The NDA submission is based primarily on the datasets derived from the Triferic Phase 3 registration study program, and includes efficacy and safety data from additional studies.
What's Next for Rockwell Medical?
Eileen Rojas, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Rockwell Medical, Inc posted a loss in its latest fourth quarter and full year 2013 report, but there appears to be a light at the end of the tunnel for its dialysis treatment business. At its current price, the company is an...
Buffett Can't Get Enough of This Stock
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 09, 7:00AM CDT
Warren Buffett's Berkshire Hathaway began scooping up shares of DaVita Healthcare Partners , a dialysis provider, back in 2011. The trend continued last week: SEC filings revealed that Berkshire purchased another 1.15 million shares. This...
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:18AM CST
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day.
Rockwell Medical to Host Investor Meeting With Nephrology Key Opinion Leader on March 6, 2014 in New York City
GlobeNewswire - Wed Mar 05, 10:47AM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will host a Key Opinion Leader Breakfast on Thursday, March 6, 2014, beginning at 8:00am Eastern Time, in New York City. Rockwell's management team will provide a brief overview of the Company's strategies to drive long-term growth, and Key Opinion Leader, Anatole Besarb, MD, will discuss how Rockwell's Triferic(TM), currently under investigation for the treatment of iron replacement in dialysis patients, will play an integral role in the anemia and renal space.
Rockwell Medical, Inc. Reports Fourth Quarter 2013 Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter and year ended December 31, 2013.
5 Hated Earnings Stocks You Should Love
at The Street - Tue Feb 25, 12:24PM CST
These heavily shorted stocks could get squeezed much higher on bullish earnings.
Rockwell Medical wins Japanese patent for Triferic
M2 - Mon Feb 24, 6:22AM CST
US-based biopharmaceutical company Rockwell Medical (NASDAQ:RMTI) revealed on Friday the receipt of the Japanese patent for its late-stage investigational iron-replacement drug Triferic, for patients with chronic kidney disease receiving hemodialysis.
Rockwell Medical Receives Japanese Patent Issuance for Triferic(TM) GMP Formulation
Marketwire - Fri Feb 21, 7:30AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Japan Patent Office that it has obtained patent issuance for its GMP formulation of Triferic, the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Rockwell Medical Schedules 4th Quarter 2013 Investor Conference Call
Marketwire - Tue Feb 18, 7:01AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss fourth quarter results on Wednesday, February 26, 2014 at 4:30pm Eastern Time. The Company plans to release results after market close the same day.
Rockwell Medical Completes Long-Term Safety Study for Iron Maintenance Drug Triferic(TM)
Marketwire - Tue Feb 04, 7:45AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced its large-scale, long-term safety study is complete. This final Phase 3 study and the two CRUISE clinical efficacy and safety studies were conducted in support of the New Drug Application (NDA) for marketing approval of Triferic. Triferic is the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Rockwell Medical, Inc. Reports First Quarter 2014 Results
GlobeNewswire - Mon May 12, 3:07PM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the first quarter ended March 31, 2014.
Rockwell Medical Schedules 1st Quarter 2014 Investor Conference Call
GlobeNewswire - Tue May 06, 9:16AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2014 at 4:30pm Eastern Time.
Marginal Earnings Beat at SurModics, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 02, 2:50PM CDT
SurModics (SRDX) reported lower-than-expected sales in the quarter.
Rockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data to be Presented at 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan
GlobeNewswire - Tue Apr 29, 7:08AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that an oral presentation and poster for Triferic will be presented at the 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Shares of RMTI Down 9.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 28, 9:32AM CDT
SmarTrend identified a Downtrend for Rockwell Medical Technologies (NASDAQ:RMTI) on April 7th, 2014 at $11.17. In approximately 3 weeks, Rockwell Medical Technologies has returned 9.54% as of today's recent price of $10.10.
Stock Watchout on Health Care Sector -- Research on Rockwell Medical, Stryker, Baxter Intl., and Covidien
PR Newswire - Tue Apr 22, 8:00AM CDT
The trading session on Monday, April 21, 2014 ended on a higher note as the S&P 500 finished the session 0.38% higher at 1,871.89 and the NASDAQ Composite closed at 4,121.55, up 0.64%. The Dow Jones Industrial Average finished at 16,449.25, up 0.25%. During the session, the eight out of ten sectors ended in positive. The S&P 500 Health Care Sector Index closed the day at 666.48, up 1.20%, and the same has advanced 1.75% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Rockwell Medical Inc. (NASDAQ: RMTI), Stryker Corp. (NYSE: SYK), Baxter International Inc. (NYSE: BAX) and Covidien PLC (NYSE: COV). Free technical research on RMTI, SYK, BAX and COV can be downloaded upon signing up at:
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Rockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data Selected for Three Abstract Presentations at National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 in Las Vegas, NV
GlobeNewswire - Mon Apr 14, 7:08AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that three individual abstracts for Triferic have been selected by the National Kidney Foundation for presentation at their Spring Clinical Meetings, April 22-26, 2014 in Las Vegas, Nevada. Triferic is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
Today’s Top Biotech Stories: Albany Molecular Research, Rockwell Medical, and Celgene
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 24, 8:16AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Albany Molecular...
Rockwell Medical Submits New Drug Application for Triferic(TM) for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis
GlobeNewswire - Mon Mar 24, 7:05AM CDT
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Triferic (soluble ferric pyrophosphate citrate), the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. The NDA submission is based primarily on the datasets derived from the Triferic Phase 3 registration study program, and includes efficacy and safety data from additional studies.
What's Next for Rockwell Medical?
Eileen Rojas, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Rockwell Medical, Inc posted a loss in its latest fourth quarter and full year 2013 report, but there appears to be a light at the end of the tunnel for its dialysis treatment business. At its current price, the company is an...
Buffett Can't Get Enough of This Stock
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 09, 7:00AM CDT
Warren Buffett's Berkshire Hathaway began scooping up shares of DaVita Healthcare Partners , a dialysis provider, back in 2011. The trend continued last week: SEC filings revealed that Berkshire purchased another 1.15 million shares. This...
Agios Pharmaceuticals (AGIO) Surges: Stock Moves 26.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 8:18AM CST
Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise by over 26% on the day.
Rockwell Medical to Host Investor Meeting With Nephrology Key Opinion Leader on March 6, 2014 in New York City
GlobeNewswire - Wed Mar 05, 10:47AM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will host a Key Opinion Leader Breakfast on Thursday, March 6, 2014, beginning at 8:00am Eastern Time, in New York City. Rockwell's management team will provide a brief overview of the Company's strategies to drive long-term growth, and Key Opinion Leader, Anatole Besarb, MD, will discuss how Rockwell's Triferic(TM), currently under investigation for the treatment of iron replacement in dialysis patients, will play an integral role in the anemia and renal space.
Rockwell Medical, Inc. Reports Fourth Quarter 2013 Results
GlobeNewswire - Wed Feb 26, 3:09PM CST
Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the fourth quarter and year ended December 31, 2013.
5 Hated Earnings Stocks You Should Love
at The Street - Tue Feb 25, 12:24PM CST
These heavily shorted stocks could get squeezed much higher on bullish earnings.
Rockwell Medical wins Japanese patent for Triferic
M2 - Mon Feb 24, 6:22AM CST
US-based biopharmaceutical company Rockwell Medical (NASDAQ:RMTI) revealed on Friday the receipt of the Japanese patent for its late-stage investigational iron-replacement drug Triferic, for patients with chronic kidney disease receiving hemodialysis.
Rockwell Medical Receives Japanese Patent Issuance for Triferic(TM) GMP Formulation
Marketwire - Fri Feb 21, 7:30AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Japan Patent Office that it has obtained patent issuance for its GMP formulation of Triferic, the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
Rockwell Medical Schedules 4th Quarter 2013 Investor Conference Call
Marketwire - Tue Feb 18, 7:01AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will hold its quarterly conference call to discuss fourth quarter results on Wednesday, February 26, 2014 at 4:30pm Eastern Time. The Company plans to release results after market close the same day.
Rockwell Medical Completes Long-Term Safety Study for Iron Maintenance Drug Triferic(TM)
Marketwire - Tue Feb 04, 7:45AM CST
Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced its large-scale, long-term safety study is complete. This final Phase 3 study and the two CRUISE clinical efficacy and safety studies were conducted in support of the New Drug Application (NDA) for marketing approval of Triferic. Triferic is the Company's late-stage investigational iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.
